Neurosteroids

Worldwide Sterols Industry to 2026 - Growing Demand from Pharmaceuticals Application - ResearchAndMarkets.com

Retrieved on:

星期五, 七月 16, 2021

Health, General Health, Nutrition, Cholestanes, Cholesterol, Neurosteroids, Sterol, Branches of biology, Health, Phytosterol

Sterols are an effective choice for reducing cholesterol levels and are safe for children as well as adults.

Key Points:

Sterols are an effective choice for reducing cholesterol levels and are safe for children as well as adults.
Additionally, people who consume a sufficient amount of sterols as a part of their diet seem to have a lower risk of gastric cancer.
The Pharmaceuticals industry is growing, owing to the rising number of diseases worldwide, which in turn is expected to drive the market for sterols in pharmeceutical industry.
Overall, such factors are expected to drive the market for sterols in the European region through the years to come.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on:

星期三, 四月 28, 2021

Cholestanes, Cholesterol, Neurosteroids, Nutrition, Branches of biology

The RSUs are subject to the terms and conditions of Esperion\xe2\x80\x99s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.\nESPERION is The Lipid Management Company.

Key Points:

The RSUs are subject to the terms and conditions of Esperion\xe2\x80\x99s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.\nESPERION is The Lipid Management Company.
Our goal is lipid management for everybody, that\xe2\x80\x99s why we work hard to make our medicines easy to get, easy to take and easy to have.
We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren\xe2\x80\x99t being met by the status quo.
We are singularly focused on managing cholesterol so you can improve your health easily.

Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

星期一, 四月 12, 2021

Biotechnology, Pharmaceutical, Health, Clinical trials, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Neurosteroids, Sterols, Chemical compounds, Ganaxolone, Chemistry

b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.

Key Points:

b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.
The stock option was granted as an inducement material to Mr. Pfanstiel entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the award agreement covering such grant.\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
Marinus undertakes no obligation to update or revise any forward-looking statements.

Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences

Retrieved on:

星期三, 二月 17, 2021

Health, Genetics, Science, Pharmaceutical, Research, GABAA receptor positive allosteric modulators, Neurosteroids, Ketones, Pregnanes, Anticonvulsants, Chemical compounds, Ganaxolone, Chemistry, Allosteric modulator, Allosteric regulation, Organic compounds

Company management will also participate in the Cowen 41st Annual Health Care Conference on March 1 at 10:20 AM (EST), the H.C. Wainwright Global Life Sciences Conference on March 9 at 3:00 PM (EST), and the Oppenheimer 31st Annual Healthcare Conference on March 16 at 8:00 AM (EST).

Key Points:

Company management will also participate in the Cowen 41st Annual Health Care Conference on March 1 at 10:20 AM (EST), the H.C. Wainwright Global Life Sciences Conference on March 9 at 3:00 PM (EST), and the Oppenheimer 31st Annual Healthcare Conference on March 16 at 8:00 AM (EST).
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.

Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences

Retrieved on:

星期一, 十月 19, 2020

Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

Key Points:

Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.
The company intends to initiate a Phase 3 trial in status epilepticus.

Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

Retrieved on:

星期一, 六月 22, 2020

GABAA receptor positive allosteric modulators, Psychoactive drugs, RTT, Anticonvulsants, Neurosteroids, Pregnanes, Chemical compounds, Medicine, Ganaxolone, Epileptic seizure

Marinus Pharmaceuticals, Inc. is apharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points:

Marinus Pharmaceuticals, Inc. is apharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
Ganaxolone is a positive allosteric modulator of GABAAreceptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects.
Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
The Company intends to initiate a Phase 3 trial in status epilepticus.

Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020

Retrieved on:

星期四, 四月 23, 2020

GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Neurosteroids, Ketones, Pregnanes, Chemical compounds, Chemistry, Ganaxolone, Allosteric regulation

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points:

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
Please follow us on Twitter: @MarinusPharma.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

星期五, 二月 14, 2020

Neurological disorders, GABAA receptor positive allosteric modulators, Organ systems, Neurosteroids, Anticonvulsants, Pregnanes, Sedatives, Ganaxolone, Nervous system, CDKL5, Marinus, Epilepsy

The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

Key Points:

The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
Ganaxolone is a positive allosteric modulator of GABAAthat acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
Marinus is conducting the first ever pivotal studies in children with CDKL5 deficiency disorder and PCDH19-related epilepsy.
Marinus undertakes no obligation to update or revise any forward-looking statements.

Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting

Retrieved on:

星期一, 二月 3, 2020

GABAA receptor positive allosteric modulators, Neurosteroids, Anticonvulsants, Ketones, Pregnanes, Ganaxolone, Organ systems, Chemistry, CDKL5, Neurology, Allosteric regulation, Epilepsy-intellectual disability in females

Ganaxolone is a positive allosteric modulator of GABAAthat acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

Key Points:

Ganaxolone is a positive allosteric modulator of GABAAthat acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
Marinus is conducting the first ever pivotal studies in children with CDKL5 deficiency disorder and PCDH19-related epilepsy.
Marinus undertakes no obligation to update or revise any forward-looking statements.

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on:

星期五, 十二月 13, 2019

GABAA receptor positive allosteric modulators, Neurosteroids, Health sciences, Health, Ketones, Pregnanes, Anticonvulsants, Neurology, Ganaxolone, Pharmaceutical industry, Allosteric modulator

The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

Key Points:

The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression.
Ganaxolone is a positive allosteric modulator of GABAAthat acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
Marinus undertakes no obligation to update or revise any forward-looking statements.